key: cord-1035906-hnnmrgzc authors: nan title: Vaccine equity: A fundamental imperative in the fight against COVID-19 date: 2022-02-22 journal: PLoS Med DOI: 10.1371/journal.pmed.1003948 sha: d13b27b20f3356fb26e700ec672488f785c681ca doc_id: 1035906 cord_uid: hnnmrgzc nan Global Accountability Platform (COVID GAP) reported that in November 2021, just 20% of the doses pledged by G7 countries had been shipped to LMICs and there are additional reports of vaccines arriving close to their expiration dates, rendering them unusable [10] . Equally essential to vaccine rollout are health infrastructure, trained medical personnel, appropriate vaccine storage facilities, accessible vaccination sites, health literacy, and public willingness to take vaccines. Furthermore, limited supplies of vital equipment such as syringes risk derailing vaccination efforts [11] , with shortfalls of between one and two billion syringes projected by the end of 2022 [12] . Scientists, academics and public health experts have collaborated to publish open letters to governments in high-income countries, recommending increased financial and operational support, and a temporary waiver of intellectual property rules to expand capacity for vaccine manufacture in LMICs themselves [13, 14] . Of particular relevance is the World Trade Organisation (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which sets the minimum standards for regulation of different forms of intellectual property applicable to WTO member nations. In May 2021, delegations from WTO members representing multiple LMICs issued a communication proposing a waiver from certain provisions of the TRIPS agreement [15] to facilitate 'the prevention, containment and treatment of COVID-19'. At the time of writing, a decision regarding the proposal is yet to be reached. Expanding vaccine manufacturing capacity in LMICs offers an opportunity to bring the current pandemic under control and to enable a more coordinated, rapid global response to the current and future pandemics. Currently, Africa imports 99% of its vaccines [16] , but the Africa Centre for Disease Control and Prevention (Africa CDC) launched the Partnership for African Vaccine Manufacturing in April 2021, with 'the proposed ambition to manufacture 60% of Africa's routine immunisation needs on the continent by 2040' [17] . With this independence comes the potential to tailor vaccines to the needs of local populations, such as in outbreak situations, and to maintain the efficacy of vaccines through improved management of the vaccine cold chain. Such an ambition will only be possible with international cooperation, including from the pharmaceutical companies that own the intellectual rights to the vaccines. Progress is being made towards increasing production of COVID-19 vaccines in Africa [18, 19] ; however, the projected annual manufacturing rates fall short of meeting the needs of the continent's 1.3 billion inhabitants [16] , particularly when factoring in the multi-dose regimen for COVID vaccines. Given that 120 pharmaceutical companies have been identified as meeting the technical and quality standards required for manufacturing sterile injectables across Asia, Africa and South America [20] , there is significant potential for introducing geographic diversity in vaccine manufacture. The right support from pharmaceutical companies, medicines regulatory authorities and national governments is essential. Achieving vaccine equity presents an essential, but substantial and highly complex, policy challenge. Beyond fundamental issues such as health infrastructure and the availability of trained personnel and medical equipment, unreliable supply and distribution of vaccines in LMICs must be addressed as a matter of urgency, and must happen alongside public health campaigns to challenge misconceptions and address vaccine concerns. Empowering LMICs to develop and/or expand their own vaccine manufacturing capabilities provides a longer-term and more sustainable solution to achieving global vaccination coverage, for COVID-19 and many other infectious diseases. Achieving this necessitates a coordinated effort across multiple agencies, requiring strong national and international leadership and formation of public-private partnerships, as well as scientific and technical expertise and public pressure to instigate change. To surmount this global pandemic, we have a collective responsibility to find a global solution. Understanding Vaccination Progress by Country-Johns Hopkins Coronavirus Resource Center Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases. EClinicalMedicine World Health Organisation. Vaccine Equity Declaration Support to Vaccine Equity; Beyond Recovery: Towards 2030 How the unvaccinated threaten the vaccinated for COVID-19: A Darwinian perspective A global database of COVID-19 vaccinations World Health Organisation. WHO Coronavirus (COVID-19) Dashboard Holding the World to Account: Urgent Actions Needed to Close Gaps in the Global COVID-19 Response. COVID Global Accountability Platform United Nations Development Programme USA. A New Hurdle in the Race to Vaccinate the World: a Syringe Shortage Does the world have the tools to inoculate billions? Program for Appropriate Technology in Health US Emergency Plan for Global COVID-19 Relief Letter to the Prime Minister from the scientific community Waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19: Communication from India and South Africa Why Africa needs to manufacture its own vaccines. Gavi, the Vaccine Alliance Africa Centre for Disease Control and Prevention. African Union and Africa CDC launches Partnerships for African Vaccine Manufacturing (PAVM), framework to achieve it and signs 2 MoUs-Africa CDC BioNTech to build mRNA vaccine facility in Africa next year. Devex Moderna plans to build mRNA vaccine manufacturing plant in Africa. Devex Pharmaceutical firms across Asia, Africa and Latin America with potential to manufacture mRNA vaccines